Diagnosis and Antimicrobial Treatment of Infections in Neonates and Children

A special issue of Antibiotics (ISSN 2079-6382).

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 7954

Special Issue Editors


E-Mail Website
Guest Editor
Institute of Medical Microbiology and Hygiene, Saarland University, 66424 Homburg, Germany
Interests: pediatric infectious diseases; antimicrobial stewardship; biomarkers; diagnostics

E-Mail Website
Guest Editor
Pediatric Oncology and Hematology, Pediatric Infectious Diseases, Children's Hospital Medical Center, Saarland University Hospital, Homburg/Saar, Germany
Interests: pediatric infectious diseases; antimicrobial stewardship; infection control and prevention; pediatric hematology and oncology

Special Issue Information

Dear Colleagues,

Infections cause a high disease burden in neonates and children and strongly contribute to pediatric morbidity and mortality worldwide. While in some settings, children may face the risk of undertreatment due to limited access to healthcare, other settings may predispose to overtreatment, especially with antibiotics. This antibiotic overuse has been identified as a main driver of antimicrobial resistance. The role of improved and clinically useful diagnostics as well as antimicrobial stewardship in pediatrics has received increasing attention in recent years. We invite colleagues to contribute to this Special Issue, which will cover both the diagnosis and antimicrobial treatment of infections in neonates and children. Priority will be given to original articles, while review articles or case reports will also be eligible. We especially welcome studies highlighting equity issues pertaining to diagnostic and/or therapeutic access, studies on diagnostic uncertainty, or innovative antimicrobial stewardship interventions in neonatology/pediatrics.

Dr. Cihan Papan
Prof. Dr. Arne Simon
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pediatric infectious diseases
  • antimicrobial stewardship
  • diagnostics
  • diagnostic uncertainty

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

10 pages, 510 KiB  
Viewpoint
Harmonization of Amoxicillin Dose, Duration, and Formulation for Acute Childhood Respiratory Infections
by Dhanya Dharmapalan, Julia Bielicki and Mike Sharland
Antibiotics 2023, 12(7), 1138; https://doi.org/10.3390/antibiotics12071138 - 30 Jun 2023
Cited by 3 | Viewed by 7553
Abstract
Pediatric guidelines vary in their recommended amoxicillin dosing for common respiratory infections. It would help program delivery if there was harmonization of dosing and formulation of amoxicillin across multiple clinical respiratory infections, considering the pharmacokinetics, common targets, drug resistance, availability, cost effectiveness, and [...] Read more.
Pediatric guidelines vary in their recommended amoxicillin dosing for common respiratory infections. It would help program delivery if there was harmonization of dosing and formulation of amoxicillin across multiple clinical respiratory infections, considering the pharmacokinetics, common targets, drug resistance, availability, cost effectiveness, and ease of administration. The World Health Organization EML AWaRe Book recommends higher dose amoxicillin given twice daily for five days for all uncomplicated respiratory infections where an antibiotic is indicated. The WHO AWaRe Book amoxicillin dosing guidance can be achieved for infants and older children using only scored 250 mg and 500 mg dispersible tablets (DTs), the WHO recommended child formulation. There is a clear need for wider availability of 250 mg/500 mg dispersible tablets of amoxicillin in both public and private health care sectors, to improve access to essential antibiotics. Full article
Show Figures

Figure 1

Back to TopTop